Stock Ratings / Health Care / SRPT / earnings

GENB (57) ZYME (49) SLS (39) TRVI (30) ⌘ Pro Terminal →

Sarepta Therapeutics Inc. (SRPT) Next Earnings Date & Expected ±10.8% Move

Q: Where is SRPT trading relative to its 50-day, 200-day, and 52-week technical levels?

SRPT last traded at $18.62 (-3.17% on volume of 1,318,230 shares), positioning the stock -3.27% below its 50-day simple moving average ($19.25) and -0.48% below its 200-day simple moving average ($18.71). Across its 52-week range of $14.68 to $24.68, SRPT sits at the 39.4% percentile with a 14-day RSI of 55.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.8% ($16.61 to $20.63).

Q: When is SRPT's next earnings date?

Based on SEC filing cadence, Sarepta Therapeutics Inc. (SRPT)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is SRPT stock expected to move on earnings?

Volatility modeling currently projects a ±10.8% event move for SRPT, spanning a range between $16.61 and $20.63.

$18.62 -3.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $18.48

Sarepta Therapeutics Inc. (SRPT) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $2.03B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SRPT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SRPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Sarepta Therapeutics Inc. (NASDAQ: SRPT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $18.62 (-3.17% 1D, market cap $2.03B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SRPT ranks #671 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SRPT compare to GENB and ZYME in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SRPT carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, GENB (Generate Biomedicines Inc.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $2.02B) and ZYME (Zymeworks Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, SRPT leads on earnings multiple (N/A) while SLS leads on capital efficiency (-21.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SRPT?

▼

Per SRPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000873303), Sarepta Therapeutics Inc. generated $1.86B in revenue (+4.3% YoY), -$713.4M in net income, and -$307.5M in free cash flow against $3.35B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $18.48 (-0.76%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRPT)Realized 20D OHLCV Swing Band: ±10.8%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY SRPT SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (31% of score)

20D Institutional Volume Accumulation (±10.8% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (23% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$17.44+1.7% Next Q

Q2 (-2Q)

Grade E$17.73+1.4% Next Q

Q3 (-1Q)

Grade E$17.98+3.6% Next Q

Current

Grade D-$18.62-8.5% Hist 90D α

Trajectory: E (27) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SRPT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SRPT currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.25) and Max Pain ($19.55) forces dealer call-delta covering toward $25.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SRPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±10.8% Swing Band

±$2.01 Expected Swing

MODEL EARNINGS SETUP GAUGE

SRPT Quantitative Pre-Earnings Setup: 35/100

Trailing EPS: $4.25 • YoY Revenue Growth: 4.3%

Model Bullish Setup (35/100)Model Risk Weight (65/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$1.86B	-$713.4M	-$307.5M	98%
FY 2024	2024-12-31	$1.79B	$235.2M	-$342.7M	92%
FY 2023	2023-12-31	$1.14B	-$536.0M	-$501.0M	92%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRPT)

✓Walkthrough of SRPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SRPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -15.52%▲ ASCENDING CHANNEL

2026-11-02O $19.32H $19.32L $18.62C $18.62VOL 1.19M

RES: $26.57SUP: $16.78SMA50: $19.25SMA200: $18.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SRPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SRPT Butterfly Map → + Track SRPT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SRPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SRPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SRPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRPT)

Health Care Rank #671 of 1016 ⚔️ GENB vs SRPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SRPT vs. GENB, ZYME, SLS, TRVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sarepta Therapeutics Inc. (SRPT) ranks #671 by composite RQD confidence (35/100, grade D-) and #261 by equity capitalization ($2.03B). Within this direct 5-issuer industry benchmark cohort, SRPT leads on earnings valuation at N/A trailing P/E, while SLS leads on capital efficiency and profitability with -21.8% ROIC and — gross margin. GENB currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with SRPT at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SRPT ACTIVE Sarepta Therapeutics Inc.	D-	35/100	—	96.0%	-35.0%	-3.17%	$2.03B	Benchmark Subject
GENB Generate Biomedicines Inc.	D+	57/100	—	—	—	-8.31%	$2.02B	/genb-vs-srpt →
ZYME Zymeworks Inc.	D	49/100	—	—	-32.2%	-0.35%	$2.02B	/zyme-vs-srpt →
SLS SELLAS Life Sciences Group Inc.	D-	39/100	—	—	-21.8%	-4.68%	$2.05B	/sls-vs-srpt →
TRVI Trevi Therapeutics Inc.	E	30/100	—	—	-23.7%	-1.81%	$1.97B	/trvi-vs-srpt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000873303

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sarepta Therapeutics Inc. (SRPT) reported GAAP revenue of $1.86B (+4.3% vs. FY2024 revenue of $1.79B , and +62.8% cumulative change since FY2023) , GAAP net income of -$713.4M, operating cash flow of -$205.5M, and free cash flow of -$307.5M (+10.3% YoY). On the balance sheet, SRPT closed FY2025 with $3.35B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.86B	-$713.4M	-$205.5M	-$307.5M	$3.35B	—
FY2024 (FY)	2024-12-31	$1.79B	$235.2M	-$205.8M	-$342.7M	$3.96B	—
FY2023 (FY)	2023-12-31	$1.14B	-$536.0M	-$501.0M	-$501.0M	—	—

3. SRPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SRPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SRPT compare to GENB and ZYME in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SRPT?

Where is SRPT trading relative to its 50-day, 200-day, and 52-week technical levels?

SRPT last traded at $18.62 (-3.17% on volume of 1,318,230 shares), positioning the stock -3.27% below its 50-day simple moving average ($19.25) and -0.48% below its 200-day simple moving average ($18.71). Across its 52-week range of $14.68 to $24.68, SRPT sits at the 39.4% percentile with a 14-day RSI of 55.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.8% ($16.61 to $20.63).

SRPT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is SRPT's next earnings date?

Based on SEC filing cadence, Sarepta Therapeutics Inc. (SRPT)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is SRPT stock expected to move on earnings?

Volatility modeling currently projects a ±10.8% event move for SRPT, spanning a range between $16.61 and $20.63.

Direct Sub-Reports: SRPT RQD Cockpit SRPT 12M Forecast SRPT Earnings & Move SRPT Dividends & DRIP SRPT Insiders & 13F SRPT Whale Options SRPT Profit Sankey SRPT News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SRPT — Sarepta Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:26:57Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SRPT scores 35/100 with a letter grade of D- and a verdict of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 5/20 (ROIC -35%; FCF yield -15.14%), Whale 13F Flow at 11/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 0.2; Piotroski F 4/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are the cash engine and insider conviction, indicating that the reported operating losses and negative free cash flow are not yet offset by evidence of insider confidence. The strongest pillar relative to its weight is institutional flow at 11/20, which suggests some institutional positioning, though the source data does not specify its direction or size. The forensic readings (Altman Z 0.2, Piotroski F 4/9) point to balance-sheet fragility. Any upside thesis would rest on the balance-sheet and cash-generation pillars improving, and the source data provides no quantified evidence of that improvement.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$1864.3M	$-699.8M	$-713.4M	N/A	$-307.5M	$801.3M	N/A
FY 2024	$1788.0M	$218.1M	$235.2M	N/A	$-342.7M	$1103.0M	N/A
FY 2023	$1144.9M	$-267.8M	$-536.0M	N/A	$-501.0M	N/A	N/A

Per the SEC financials and market data, FY 2025 shows an operating margin of -37.5% and net margin of -38.3%, with ROIC of -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9, both consistent with financial stress. Debt/Equity is 0.5 per the RQD rating. Cash declined from $1103.0M (FY 2024) to $801.3M (FY 2025), and free cash flow was negative in all three reported periods.

Recent Catalysts & News Wire Analysis

Per the recent news section, the items include: a Yahoo Finance report on analyst hesitation (headline states that Jim Cramer explained his hesitation over SRPT); a Sarepta release presenting preclinical data on SRP-1003 in DM1 at the 2026 Oligonucleotide Therapeutics Society Annual Meeting; a Stocktwits report on an analyst seeing 34% upside; a TradingView and Yahoo! Finance Canada quote page; and a Simply Wall St piece titled "Two Stories Ran On Sarepta Therapeutics. Only One Held Up." The news feed carries a GREEN light on the Stocktwits item (CATALYST) and YELLOW lights on the others (MARKET WIRE). Risk watch items include the DM1 program remaining at preclinical stage per the Sarepta release and the negative free cash flow trend. The Butterfly supply-chain graph reports no supply chain and no proprietary signals.

Open Questions

What are the specific revenue drivers behind FY 2025 revenue of $1864.3M, and how does that relate to the swing from positive FY 2024 operating income to a loss in FY 2025?
What is the debt balance, since the debt field is N/A across all periods while Debt/Equity is cited as 0.5?
What is the expected path to positive free cash flow given cash fell from $1103.0M to $801.3M?
What is the commercial status and timeline of the SRP-1003 DM1 program referenced in the news?
What is the EPS history, since EPS is N/A in every reported period?

SRPT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sarepta Therapeutics Inc. (SRPT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SRPT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 12h ago

Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics

Yahoo Finance report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Sarepta Therapeutics • 15h ago

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

Sarepta Therapeutics report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stocktwits • 18h ago

This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next

Stocktwits report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 21h ago

Sarepta Therapeutics, Inc. News — BMV:SRPT

TradingView report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Two Stories Ran On Sarepta Therapeutics. Only One Held Up

Simply Wall St report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 1d ago

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

Business Wire report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stocktwits • 1d ago

SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling

Stocktwits report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SRPT Bull vs. Bear Conversation Board — What's Your Call at $18.62?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SRPT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $16.92 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SRPT (D- • RQD 35/100) a Buy at $19.23?

Welcome to the SRPT (Sarepta Therapeutics Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $16.15 (-16.0%)

Spot @ $19.23

Pump the brakes on SRPT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SRPT, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless Sarepta Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $22.88 (+19.0%)

Spot @ $19.23

SRPT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SRPT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $19.23 (52-wk range $14.68 - $24.68), any beat on forward guidance forces shorts and underweight funds to chase.